Transcript
As the US nears five-million cases, the race for a coronavirus vaccine continues.
Wednesday US drug company Moderna said it plans to make its vaccine affordable, below 40-dollars per dose for most customers.
This comes all drug companies are being closely watched to see what they plan to charge for Covid-19 treatments.
In June biotech company Gilead Sciences revealed that its remdesivir drug will cost more than 500-dollars a vial for people with private health insurance.
Also Wednesday Moderna said that it’s on track to finish enrolling people for phase three study before October.
Moderna is just one of several US companies racing to come up with a successful vaccine.
Novavax and Pfizer has also had promising vaccine results so far.
Posted – 8.5.20